Menu

Mitochondrial DNA Plays a Role in Metastasis

Experiments in mice show that mitochondria, both within the tumor and beyond, can make the difference between promoting or inhibiting cancer spread.

Apr 18, 2018
Kerry Grens

ISTOCK, WIR0MANThe mitochondrial genome of mice is only 16 kilobases long, comprising just 37 genes, yet its polymorphisms appear related to the metastatic potential of cancer, researchers report at the American Association of Cancer Research annual meeting in Chicago today (April 17). Researchers swapped the nuclear and mitochondrial DNA among several mouse strains and observed changes in immune function, microbiome composition, metabolomics, and tumor spread that tracked with mitochondrial type.

“People just assume something of 16 kilobases couldn’t be that critical for something so complicated,” Danny Welch, a cancer biologist at the University of Kansas Medical Center who presented his lab’s results, tells The Scientist.

The latest, unpublished findings build upon a 2017 report in Cancer Research by Welch’s group that showed that the mitochondrial genome was tied to the speed of cancer growth and metastasis. Mice of a strain called FVB that had inherited mitochondria from either of two other strains took longer to form tumors and had less tumor spread than mice with native FVB mitochondria, Welch and his colleagues reported.

In the latest experiments, the researchers took cancer cells with the mouse strains’ original nuclear and mitochondrial genomic backgrounds and infused them into mice with either original or swapped mitochondrial DNA. This set-up gave the investigators a look at how mitochondrial DNA in tissues outside the tumor might affect cancer spread. Again, the team found that the amount of metastases was tied to mitochondrial type. “We were so shocked by the data we repeated it three times over the course of the year with 10 mice per experiment,” Welch said during his presentation.

The new data point to possible hints as to how mitochondria might contribute to metastasis—namely, Welch and colleagues found immune, microbial, and metabolic, changes associated with mitochondrial background that they are now pursuing with follow up investigations.

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
NRGene has launched a new product that aims to empower breeding and maximize agricultural yield as part of the Denovo assembly product suite offered by the company.
Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas, Inc., an emerging diagnostic company, launched a portfolio of products that can improve the accuracy of current diagnostic test results by helping laboratory professionals detect and manage biotin interference in patient samples with VeraTest Biotin and VeraPrep Biotin.
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
Scientists presented more than 30 abstracts featuring Bio-Rad’s Droplet Digital PCR (ddPCR) technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31–June 4.